Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 11/20 | 0.65 |
| ▸ | KCNK9 | Q9NPC2 | 9/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.60 |
| ▸ | MEN1 | O00255 | 4/20 | 0.60 |
| ▸ | NPC1 | O15118 | 3/20 | 0.60 |
| ▸ | RAB9A | P51151 | 3/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | NT5E | P21589 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18500990 | 0.87 | LMNA (0.65) | KCNK3KCNK9KMT2AMEN1NPC1 | |
| SCHEMBL25896982 | 0.85 | KCNK3 (0.70) | KCNK3KCNK9KCNH2KMT2AMEN1 | |
| SCHEMBL22337424 | 0.83 | MEN1 (0.59) | KCNK3KCNK9KMT2AMEN1RAB9A | |
| SCHEMBL17409720 | 0.83 | KCNK3 (0.70) | KCNK3KCNK9KCNH2KMT2AMEN1 | |
| SCHEMBL12218052 | 0.78 | NPC1 (0.72) | KCNK3KCNK9KCNH2KMT2AMEN1 | |
| SCHEMBL4253897 | 0.77 | KCNK3 (0.93) | KCNK3KCNK9KCNH2KMT2AMEN1 | |
| SCHEMBL22629693 | 0.77 | KCNK3 (0.74) | KCNK3KCNK9KCNH2KMT2AMEN1 | |
| SCHEMBL30048093 | 0.76 | NPC1 (0.81) | KCNK3KCNK9KCNH2KMT2AMEN1 | |
| SCHEMBL4257440 | 0.76 | NPC1 (0.81) | KCNK3KCNK9KCNH2KMT2AMEN1 | |
| SCHEMBL16675166 | 0.75 | KCNK3 (0.89) | KCNK3KCNK9KCNH2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11725011-B2 | Bicyclic urea kinase inhibitors and uses thereof | THE GENERAL HOSPITAL CORPORATION (US) | 2023-08-15 | — | — | US | disclosed |
| US-20230234959-A1 | BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234959-A1 | BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF | SIK1, SIK2, SIK3 | KCNK3 640/4885KCNK9 671/4885KCNH2 3525/4885 |
| US-11725011-B2 | Bicyclic urea kinase inhibitors and uses thereof | SIK1, SIK2, SIK3 | KCNK3 640/4885KCNK9 671/4885KCNH2 3525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.